Tag : PV-ARC

  • CONFERENCE UPDATE
    Revised ELN criteria improve thrombotic risk stratification in PV: Findings from the PV-ARC study

    Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by uncontrolled red blood cell production and a heightened likelihood of thrombosis.1 PV is traditionally classified into low- and high-risk categories, with the latter indicated for cytoreductive therapy, primarily with hydroxyurea (HU). The revised European LeukemiaNet (ELN) criteria expands on 6 clinical signs and symptoms (CSSs) to guide the initiation of cytoreductive therapy, yet their impact on thrombotic risk across conventional risk categories remains underexplored. This study evaluated the incidence of thrombotic events among patients with PV receiving HU and investigated the role of revised ELN criteria for cytoreductive therapy start (CTS) in identifying high-risk phenotypes. Findings from the multicenter PV-ARC study were presented by Dr. Francesca Palandri at the ASH Annual Meeting & Exposition 2024.